Physician profile
Ana Pena
NPI 1013285154
$3,439.44
in general payments reported to CMS, 2019-2025
27 companies · $728 in 2025
The $728 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $880 · 2022: $608 · 2023: $765 · 2024: $458 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $482.33 | 2021-2025 | |
| Lilly USA, LLC | $345.19 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.15 | 2021-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $308.22 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $266.27 | 2022-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $247.59 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Radius Health, INC. | $206.12 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $176.75 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $125.90 | 2021-2025 | Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $115.12 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $107.32 | 2021-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $99.61 | 2021-2023 | |
| Pfizer INC. | $83.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $78.89 | 2021-2025 | |
| Esperion Therapeutics, INC. | $73.56 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $55.13 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $45.68 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $45.49 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $39.69 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $37.57 | 2021-2022 | |
| Depuy Synthes Sales INC. | $33.75 | 2022 | |
| Viiv Healthcare Company | $29.00 | 2025 | Apretude |
| Abbott Laboratories | $21.48 | 2021 | |
| Mannkind Corporation | $21.44 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.59 | 2021 | |
| Astellas Pharma US INC | $16.56 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.